Atorvastatin regulates vascular smooth muscle cell phenotypic transformation by epigenetically modulating contractile proteins and mediating Akt/FOXO4 axis

Du,Xinping; Sun,Zhiyuan; Cao,Zhongnan; Zhou,Xiuhong; Wang,Dong; Wang,Kuan; Li,Xuebin; Zuo,Guoxing

doi:10.3892/mmr.2022.12683

Atorvastatin regulates vascular smooth muscle cell phenotypic transformation by epigenetically modulating contractile proteins and mediating Akt/FOXO4 axis

Authors:
- Xinping Du
- Zhiyuan Sun
- Zhongnan Cao
- Xiuhong Zhou
- Dong Wang
- Kuan Wang
- Xuebin Li
- Guoxing Zuo
View Affiliations

Affiliations: Department of Cardiology, Tianjin Fifth Central Hospital, Tianjin 300450, P.R. China, Department of Cardiology, Tianjin Fifth Central Hospital, Tianjin 300450, P.R. China
Published online on: March 16, 2022 https://doi.org/10.3892/mmr.2022.12683
Article Number: 167

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Atherosclerosis (AS) is a prevalent cardiovascular disease with severe morbidity and high mortality. Phenotypic regulation of vascular smooth muscle cells (VSMCs) from the contractile and quiescent phenotype to the synthetic type is a critical step for the vascular remodeling of AS. Atorvastatin, as a 3‑hydroxy‑3‑methyl‑glutaryl coenzyme A reductase inhibitor, presents an anti‑inflammatory effect to improve vascular endothelial functions. The aim of the present study was to examine the effect of atorvastatin on VSMCs phenotypic transformation and the underlying mechanism. The rat primary VSMCs were isolated and identified. The protein expression of contractile proteins, such as α‑SMA, SM‑MHC, and SM22α, was reduced by angiotensin II (AngII) and enhanced by atorvastatin, in which atorvastatin could reverse the effect of AngII in the VSMCs. The treatment of HDAC inhibitor trichostatin A was able to enhance AngII‑inhibited expression of α‑SMA and SM‑MHC. Atorvastatin regulated AngII‑associated VSMCs phenotypic transformation by epigenetically regulating contractile proteins. Moreover, atorvastatin modulated platelet‑derived growth factor‑BB (PDGF‑BB)‑induced VSMC phenotypic transformation by modulating the Akt/forkhead Box O4 (FOXO4) axis. Immunofluorescence analysis revealed that PDGF‑BB enhanced the accumulation of FOXO4 in the VSMCs, while the treatment of atorvastatin was able to attenuate this effect and the co‑treatment of Akt inhibitor LY294002 could further inhibit the phenotype. The treatment of PDGF‑BB enhanced the interaction of SRF with FOXO4 and myocardin in the VSMCs, in which the co‑treatment of atorvastatin and LY294002 could reverse the effect of PDGF‑BB in the system. Thus, atorvastatin regulates VSMCs phenotypic transformation by epigenetically modulating contractile proteins and mediating the Akt/FOXO4 axis. Findings of the present study provide new insights into the mechanism by which atorvastatin modulates VSMCs, providing valuable evidence for the application of atorvastatin in the treatment of AS.

View Figures

View References

1	Peng J, Xiao X, Hu M and Zhang X: Interaction between gut microbiome and cardiovascular disease. Life Sci. 214:153–157. 2018. View Article : Google Scholar : PubMed/NCBI
2	Nitsa A, Toutouza M, Machairas N, Mariolis A, Philippou A and Koutsilieris M: Vitamin D in cardiovascular disease. In Vivo. 32:977–981. 2018. View Article : Google Scholar : PubMed/NCBI
3	Leong DP, Joseph PG, McKee M, Anand SS, Teo KK, Schwalm JD and Yusuf S: Reducing the global burden of cardiovascular disease, part 2: Prevention and treatment of cardiovascular disease. Circ Res. 121:695–710. 2017. View Article : Google Scholar : PubMed/NCBI
4	Schaftenaar F, Frodermann V, Kuiper J and Lutgens E: Atherosclerosis: The interplay between lipids and immune cells. Curr Opin Lipidol. 27:209–215. 2016. View Article : Google Scholar : PubMed/NCBI
5	Barrington WT and Lusis AJ: Atherosclerosis: Association between the gut microbiome and atherosclerosis. Nat Rev Cardiol. 14:699–700. 2017. View Article : Google Scholar : PubMed/NCBI
6	He X, Lian Z, Yang Y, Wang Z, Fu X, Liu Y, Li M, Tian J, Yu T and Xin H: Long Non-coding RNA PEBP1P2 suppresses proliferative VSMCs phenotypic switching and proliferation in atherosclerosis. Mol Ther Nucleic Acids. 22:84–98. 2020. View Article : Google Scholar : PubMed/NCBI
7	Xu J, Zhang Y, You S, Guo Y, Chen S, Chang Y, Zhang N and Sun Y: Paired box 9 regulates VSMC phenotypic transformation, proliferation, and migration via sonic hedgehog. Life Sci. 257:1180532020. View Article : Google Scholar : PubMed/NCBI
8	Fu Y, Chang Y, Chen S, Li Y, Chen Y, Sun G, Yu S, Ye N, Li C and Sun Y: BAG3 promotes the phenotypic transformation of primary rat vascular smooth muscle cells via TRAIL. Int J Mol Med. 41:2917–2926. 2018.PubMed/NCBI
9	Lu QB, Wan MY, Wang PY, Zhang CX, Xu DY, Liao X and Sun HJ: Chicoric acid prevents PDGF-BB-induced VSMC dedifferentiation, proliferation and migration by suppressing ROS/NFĸB/mTOR/P70S6K signaling cascade. Redox Biol. 14:656–668. 2018. View Article : Google Scholar : PubMed/NCBI
10	Zhang M, Li F, Wang X, Gong J, Xian Y, Wang G, Zheng Z, Shang C, Wang B, He Y, et al: MiR-145 alleviates Hcy-induced VSMC proliferation, migration, and phenotypic switch through repression of the PI3K/Akt/mTOR pathway. Histochem Cell Biol. 153:357–366. 2020. View Article : Google Scholar : PubMed/NCBI
11	Song W, Gao K, Huang P, Tang Z, Nie F, Jia S and Guo R: Bazedoxifene inhibits PDGF-BB induced VSMC phenotypic switch via regulating the autophagy level. Life Sci. 259:1183972020. View Article : Google Scholar : PubMed/NCBI
12	Taniguti EH, Ferreira YS, Stupp IJV, Fraga-Junior EB, Doneda DL, Lopes L, Rios-Santos F, Lima E, Buss ZS, Viola GG and Vandresen-Filho S: Atorvastatin prevents lipopolysaccharide-induced depressive-like behaviour in mice. Brain Res Bull. 146:279–286. 2019. View Article : Google Scholar : PubMed/NCBI
13	Li S, Yu Y, Jin Z, Dai Y, Lin H, Jiao Z, Ma G, Cai W, Han B and Xiang X: Prediction of pharmacokinetic drug-drug interactions causing atorvastatin-induced rhabdomyolysis using physiologically based pharmacokinetic modelling. Biomed Pharmacother. 119:1094162019. View Article : Google Scholar : PubMed/NCBI
14	Kogawa AC, Pires AEDT and Salgado HRN: Atorvastatin: A review of analytical methods for pharmaceutical quality control and monitoring. J AOAC Int. 102:801–809. 2019. View Article : Google Scholar : PubMed/NCBI
15	Ginnan R, Sun LY, Schwarz JJ and Singer HA: MEF2 is regulated by CaMKIIδ2 and a HDAC4-HDAC5 heterodimer in vascular smooth muscle cells. Biochem J. 444:105–114. 2012. View Article : Google Scholar : PubMed/NCBI
16	Zhao G, Fu Y, Cai Z, Yu F, Gong Z, Dai R, Hu Y, Zeng L, Xu Q and Kong W: Unspliced XBP1 Confers VSMC homeostasis and prevents aortic aneurysm formation via FoxO4 Interaction. Circ Res. 121:1331–1345. 2017. View Article : Google Scholar : PubMed/NCBI
17	Huang C, Huang W, Wang R and He Y: Ulinastatin inhibits the proliferation, invasion and phenotypic switching of PDGF-BB-Induced VSMCs via Akt/eNOS/NO/cGMP signaling pathway. Drug Des Devel Ther. 14:5505–5514. 2020. View Article : Google Scholar : PubMed/NCBI
18	Lu W, Ni Z, Jiang S, Tong M, Zhang J, Zhao J, Feng C, Jia Q, Wang J, Yao T, et al: Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway. Phytother Res. 35:1495–1507. 2021. View Article : Google Scholar : PubMed/NCBI
19	Zhou N, Lee JJ, Stoll S, Ma B, Wiener R, Wang C, Costa KD and Qiu H: Inhibition of SRF/myocardin reduces aortic stiffness by targeting vascular smooth muscle cell stiffening in hypertension. Cardiovasc Res. 113:171–182. 2017. View Article : Google Scholar : PubMed/NCBI
20	Qin X, Hou X, Zhang M, Liang T, Zhi J, Han L and Li Q: Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs. Int J Mol Sci. 15:6641–6656. 2014. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Tikoo K, Patel G, Kumar S, Karpe PA, Sanghavi M, Malek V and Srinivasan K: Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modifications. Biochem Pharmacol. 93:343–351. 2015. View Article : Google Scholar : PubMed/NCBI
23	Wu LM, Wu SG, Chen F, Wu Q, Wu CM, Kang CM, He X, Zhang RY, Lu ZF, Li XH, et al: Atorvastatin inhibits pyroptosis through the lncRNA NEXN-AS1/NEXN pathway in human vascular endothelial cells. Atherosclerosis. 293:26–34. 2020. View Article : Google Scholar : PubMed/NCBI
24	Chen S, Dong S, Li Z, Guo X, Zhang N, Yu B and Sun Y: Atorvastatin calcium inhibits PDGF-ββ-induced proliferation and migration of VSMCs Through the G0/G1 cell cycle arrest and suppression of activated PDGFRbeta-PI3K-Akt signaling cascade. Cell Physiol Biochem. 44:215–228. 2017. View Article : Google Scholar : PubMed/NCBI
25	Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ and Egido J: 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis. 161:17–26. 2002. View Article : Google Scholar : PubMed/NCBI
26	Pietruczuk P, Jain A, Simo-Cheyou ER, Anand-Srivastava MB and Srivastava AK: Protein kinase B/AKT mediates insulin-like growth factor 1-induced phosphorylation and nuclear export of histone deacetylase 5 via NADPH oxidase 4 activation in vascular smooth muscle cells. J Cell Physiol. 234:17337–17350. 2019. View Article : Google Scholar : PubMed/NCBI
27	Okamoto H, Fujioka Y, Takahashi A, Takahashi T, Taniguchi T, Ishikawa Y and Yokoyama M: Trichostatin A, an inhibitor of histone deacetylase, inhibits smooth muscle cell proliferation via induction of p21(WAF1). J Atheroscler Thromb. 13:183–191. 2006. View Article : Google Scholar : PubMed/NCBI
28	Iaconetti C, De Rosa S, Polimeni A, Sorrentino S, Gareri C, Carino A, Sabatino J, Colangelo M, Curcio A and Indolfi C: Down-regulation of miR-23b induces phenotypic switching of vascular smooth muscle cells in vitro and in vivo. Cardiovasc Res. 107:522–533. 2015. View Article : Google Scholar : PubMed/NCBI
29	Qu C, Liu X, Guo Y, Fo Y, Chen X, Zhou J and Yang B: MiR-128-3p inhibits vascular smooth muscle cell proliferation and migration by repressing FOXO4/MMP9 signaling pathway. Mol Med. 26:1162020. View Article : Google Scholar : PubMed/NCBI
30	Gong C, Ai J, Fan Y, Gao J, Liu W, Feng Q, Liao W and Wu L: NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling. Onco Targets Ther. 12:8537–8552. 2019. View Article : Google Scholar : PubMed/NCBI